RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
The FTC closes its probe into Roche’s (OTCQX:RHHBY) $4.8B acquisition of Spark Therapeutics (NASDAQ:ONCE).
The agency won’t require any asset sales for the merger to comply with antitrust laws.
The FTC says the investigation “did not indicate that Roche would have the incentive to delay or terminate Spark’s developmental effort for its hemophilia A gene therapy, or that the acquisition would affect Roche’s incentives” for its hemophilia drug.
The FDA’s Oncologic Drugs Advisory Committee will meet on Tuesday, December 17, to review and discuss AstraZeneca’s (AZN +2%) marketing application for Lynparza (olaparib) for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic adenocarcinoma of the pancreas whose disease has not progressed on first-line platinum-based chemotherapy.
Immune Therapeutics (OTCPK:IMUN -4.8%) will acquire privately held Aletheia Therapeutics in an all-stock transaction.
The deal should close next quarter.
Dicerna Pharmaceuticals (DRNA +1.6%) and collaboration partner Alexion Pharmaceuticals (ALXN +0.8%) announce that the latter has exercised its option for exclusive rights to two additional GalXC RNAi targets within the complement pathway, increasing the number of programs to four.
Alexion will pay Dicerna $20M for the two licenses.
Astellas Pharma (OTCPK:ALPMF) and development/commercialization partner Pfizer (NYSE:PFE) announce FDA approval of Xtandi (enzalutamide) for the treatment of men with metastatic castration-sensitive prostate cancer, a type of prostate cancer that affects ~40K Americans.
The androgen receptor inhibitor was approved in the U.S. in August 2012 for metastatic castration-resistant prostate cancer and in July 2018 for non-metastatic castration-resistant prostate cancer.
